Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Retained Earnings (2016 - 2026)

Protara Therapeutics' Retained Earnings history spans 14 years, with the latest figure at -$320.2 million for Q1 2026.

  • Quarterly Retained Earnings fell 359876.4% to -$320.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$320.2 million through Mar 2026, down 359876.4% year-over-year, with the annual reading at -$302.4 million for FY2025, 15121050.0% down from the prior year.
  • Retained Earnings came in at -$320.2 million for Q1 2026, down from -$302.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $89000.0 in Q1 2025 to a low of -$320.2 million in Q1 2026.
  • The 5-year median for Retained Earnings is -$121.0 million (2022), against an average of -$130.5 million.
  • Year-over-year, Retained Earnings skyrocketed 117.58% in 2024 and then tumbled 15121050.0% in 2025.
  • Protara Therapeutics' Retained Earnings stood at -$688000.0 in 2022, then crashed by 29025.58% to -$200.4 million in 2023, then surged by 100.0% to $2000.0 in 2024, then crashed by 15121050.0% to -$302.4 million in 2025, then fell by 5.88% to -$320.2 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Retained Earnings are -$320.2 million (Q1 2026), -$302.4 million (Q4 2025), and -$285.1 million (Q3 2025).